MRTX stock extends losses as Stifel says selloff is overdone (NASDAQ:MRTX)
seekingalpha.com
finance
2022-05-27 12:30:55

naphtalina/iStock via Getty Images Mirati Therapeutics (NASDAQ:MRTX) continued to trade lower in the pre-market Friday after the clinical-stage oncology company updated data for its KRAS inhibitor, adagrasib, while Stifel defended the stock noting that the post-market selloff was 'overdone.' The data were generated from a registration-enabling Phase 2 cohort of the KRYSTAL-1 study, which involved patients with non-small cell lung cancer (NSCLC) who underwent at least one prior systemic therapy. The results indicated an 80% of median progression-free survival ((mPFS)) and 12.
